CytoDyn appoints Robert E. Hoffman as CFO effective May 15, 2025

CytoDyn Inc.

Hoffman replaces interim CFO Mitch Cohen; Cohen resigns effective May 12 with last day May 30.
Compensation includes $450,000 base salary, 40% target bonus, option for 1M shares, PSUs for 3.5M shares.
Hoffman has 30+ years biotech experience; previously CFO at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals.
Hoffman currently serves on boards of Esperion Therapeutics, TuHURA Biosciences, and Fibrobiologics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert E. Hoffman

Chief Financial Officer

CYDY · CytoDyn Inc.

Effective: 2025-05-15
Filed: May 6, 2025, 7:59 PM ET

On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Hoffman was appointed as Chief Financial Officer at CytoDyn Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-006531

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.